A phase I clinical trial demonstrates that nfP2X7‐targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles